Remarkably, our observations also indicate that in contrast to the collective action of EphB receptors, EphB6 does not support survival of T-ALL cells, but rather increases their sensitivity both in cell culture and in vivo to a DNA-damaging therapeutic compound, doxorubicin, that is being commonly used for T-All treatment11,28. Here, EPHB6 is linked to acute lymphoblastic leukemia.